Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

IGM Biosciences Halts Further Development Of Imvotamab And IGM-2644; Plans Reducing Its Workforce By 73%

Author: Benzinga Newsdesk | January 09, 2025 01:10pm

"Interim data from the Phase 1b studies of imvotamab in rheumatoid arthritis and systemic lupus erythematosus show that the depth and consistency of B cell depletion is insufficient to meet our high bar for success," said Mary Beth Harler, M.D., Chief Executive Officer of IGM Biosciences.

The Company reported cash and investments of approximately $183.8 million (unaudited) as of December 31, 2024.

Posted In: IGMS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist